Accel Wealth Management’s Gilead Sciences GILD Stock Holding History

Accel Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-109	Closed	-$9.06K	–	436
2023 Q1	$9.06K	Hold	109	–	–	﹤0.01%	920
2022 Q4	$9.36K	Hold	109	–	–	﹤0.01%	722
2022 Q3	$7K	Hold	109	–	–	﹤0.01%	800
2022 Q2	$7K	Hold	109	–	–	﹤0.01%	762
2022 Q1	$6K	Sell	109 -22	-17%	-$1.41K	﹤0.01%	784
2021 Q4	$9K	Buy	131 +31	+31%	+$2.13K	﹤0.01%	727
2021 Q3	$7K	Sell	100 -30	-23%	-$2.11K	﹤0.01%	701
2021 Q2	$9K	Sell	130 -379	-74%	-$25.3K	0.01%	709
2021 Q1	$33K	Buy	509 +3	+0.6%	+$193	0.03%	398
2020 Q4	$30K	Buy	+506	New	+$30.5K	0.03%	404

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Accel Wealth Management's GILD Position: Q2 2023 in Review

Accel Wealth Management sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 109 shares — an estimated $9.06K sold.

Accel Wealth Management first reported a position in GILD in Q4 2020 and held it in 10 quarters. The position peaked at $33K in Q1 2021. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

Accel Wealth Management reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
Accel Wealth Management sold 109 Gilead Sciences shares in Q2 2023, an estimated $9.06K.
Accel Wealth Management first reported a position in Gilead Sciences in Q4 2020 and held it in 10 quarters.
Accel Wealth Management's Gilead Sciences position peaked at $33K in Q1 2021.
1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.